Skip to content

PressReach

SEARCH

Investing
Featured
Market
Biotech
Oil & Gas
Mining
Gaming
Tech
Crypto
More

Search

SEARCH FOR AN ARTICLE

Search

Investing
Featured
Market
Biotech
Oil & Gas
Mining
Gaming
Tech
Crypto
More

PressReach

Home(Nasdaq: FULC)

(Nasdaq: FULC)

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

July 5, 2022

LATEST NEWS

Investing News Live Nation’s Earnings Shine
Investing News Cisco Q1 FY2025 Earnings Overview
Investing News Marathon Digital’s Earnings Insights
Investing News Mosaic Stock Drops Due to Hurricanes
Investing News Spotify’s Q3 FY2024 Earnings Overview

PressReach

All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

Advertisers
Privacy Policy
Terms of Use
DMCA Policy
Disclaimer
Contact Us

SUBSCRIBE

To get email updates from PressReach.

I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

Market Jar Media Inc. © 2024